Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Hosted on MSN12h
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
TipRanks on MSN16h
AbbVie price target lowered to $205 from $215 at CitiCiti lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Blue Tower Asset Management's Global Value strategy returned 4.95% in Q4 (5.23% gross) and 22.27% net for 2024 (23.53% gross) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback